Kathy, these approaches may be very efficacious. Being patient specific, they may be very costly and present bottlenecks in production that a less individual approach may avoid. You may want to look at Cell Genesys in addition to the two companies you have mentioned. They are very well capitalized, still a ten percent owner of Abgenix, I believe, which they spun off some time ago and which is a testament to Cell Genesys' business and scientific acumen. My understanding is that Cell Genesys engineers the gene for granulocyte-macrophage colony stimulating factor (GMCSF) into tumor cells using two approaches, one patient specific, the other not. These provoke the patient's immune system to attack the tumor. They have a number of things in phase 2 clinical trials and plan to initiate a phase 3 trial mid-2003 for their GVAX prostate cancer vaccine. In addition, they have upwards of 200 gene therapy patents. Personally, I think this is one company with legs.
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. M